Breaking News, Collaborations & Alliances

Fujifilm Diosynth to Manufacture Lilly COVID-19 Antibody

Commercial manufacturing of the antibody therapy is expected to commence in April 2021.

By: Contract Pharma

Contract Pharma Staff

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator.   The commercial manufacturing falls under the agreement between Lilly and the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator to su...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters